TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease

TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH.

Under the terms of the agreement, Biogen and TRIMTECH will work collaboratively to discover and develop small molecule protein degraders for the treatment of neurodegenerative diseases. Upon Biogen's exercise of the option, the company will be granted a global exclusive license to the degraders developed and will be responsible for further development and commercialization activities. Under the terms of the agreement, TRIMTECH is eligible to receive up to $32 million in upfront and research milestone payments, with total potential payments of up to $411 million, plus royalties.

We are excited to enter this strategic collaboration with Biogen, which is a major milestone for TRIMTECH. This is a significant validation of the progress we have made and the potential of our TRIM21-based targeted protein degradation platforms. Combining our expertise with Biogen's strong legacy and experience in developing treatments for neurodegenerative diseases brings new promise to the potential of delivering more effective therapies for patients."

Dr Nicki Thompson, CEO, TRIMTECH Therapeutics

Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, TRIMTECH has demonstrated its small molecule TRIMTAC® and TRIMGLUE® degraders can access the CNS and selectively degrade toxic protein aggregates and oligomers underpinning many neurodegenerative diseases. This opens-up much needed small molecule treatment options and offers the potential to transform the course of treatment for the millions of patients battling these diseases.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    TRIMTECH Therapeutics. (2026, November 16). TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease. News-Medical. Retrieved on November 16, 2026 from https://www.news-medical.net/news/20261116/TRIMTECH-Therapeutics-enters-strategic-research-collaboration-with-Biogen-to-advance-small-molecule-degraders-for-neurodegenerative-disease.aspx.

  • MLA

    TRIMTECH Therapeutics. "TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease". News-Medical. 16 November 2026. <https://www.news-medical.net/news/20261116/TRIMTECH-Therapeutics-enters-strategic-research-collaboration-with-Biogen-to-advance-small-molecule-degraders-for-neurodegenerative-disease.aspx>.

  • Chicago

    TRIMTECH Therapeutics. "TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease". News-Medical. https://www.news-medical.net/news/20261116/TRIMTECH-Therapeutics-enters-strategic-research-collaboration-with-Biogen-to-advance-small-molecule-degraders-for-neurodegenerative-disease.aspx. (accessed November 16, 2026).

  • Harvard

    TRIMTECH Therapeutics. 2026. TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease. News-Medical, viewed 16 November 2026, https://www.news-medical.net/news/20261116/TRIMTECH-Therapeutics-enters-strategic-research-collaboration-with-Biogen-to-advance-small-molecule-degraders-for-neurodegenerative-disease.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio